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Abstract
Background & Objectives—Genes encoding protein C anticoagulant pathways are candidates
for athero-thrombotic and other aging-related disorders.
Methods—Using a tagSNP approach, and data from the Cardiovascular Health Study (CHS), we
assessed associations of common polymorphisms of PROC, PROS1, and PROCR with (1) plasma
protein C, soluble protein C receptor (sEPCR), and protein S levels measured in a sub-sample of
336 participants at study entry; (2) risk of incident clinical outcomes (coronary heart disease or
CHD, stroke, and mortality) in 4,547 participants during follow-up. Secondarily, we explored
associations between plasma protein C, S, and sEPCR levels and other candidate genes involved
in thrombosis, inflammation, and aging.
Results—The PROCR Ser219Gly polymorphism (rs867186) was strongly associated with higher
sEPCR levels, explaining 75% of the phenotypic variation. The Ser219Gly variant was also
associated with higher levels of circulating protein C antigen. An IL10 polymorphism was
associated with higher free protein S levels. The minor alleles of PROC rs2069901 and PROS1
rs4857343 were weakly associated with lower protein C and free protein S levels, respectively.
There was no association between PROCR Ser219Gly and risk of CHD, stroke, or mortality. The
minor allele of another common PROCR tagSNP, rs2069948, was associated with lymphoid
PROCR mRNA expression and with increased risk of incident stroke and all-cause mortality, and
decreased healthy survival during follow-up.
Conclusions—A common PROCR variant may be associated with decreased healthy survival in
older adults. Additional studies are warranted to establish the role of PROCR variants in ischemic
and aging-related disorders.
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Protein C is activated on endothelium by the thrombin-thrombomodulin-endothelial protein
C receptor (EPCR) complex [1]. In the presence of cofactor protein S, activated protein C
(APC) proteolytically inactivates coagulation factors VIIIa and Va, thereby inhibiting clot
formation. By binding to EPCR and protease-activated receptor-1, APC also exerts anti-
inflammatory and cytoprotective effects on a variety of cell types [2].
The Ser219Gly variant (rs867186) tags a common PROCR haplotype, and is associated with
higher soluble EPCR (sEPCR) levels, explaining ~85% of the phenotypic variance [3,4].
The heritabilities of circulating protein C, free protein S, and total protein S range between
30–50% [5,6], but the specific genetic factors responsible are not as well characterized [7,8].
Promoter polymorphisms of the protein C gene (PROC) have been reported to account for
~5% of the phenotypic variability [9,10].
Mutations and polymorphisms of PROC, PROCR, and PROS1 (coding for protein S) are
associated with risk of familial venous thrombotic disease. Recently, the PROCR Ser219Gly
variant was associated with increased thrombin generation and increased risk of coronary
heart disease (CHD) in men from the Northwick Park Heart Study [11]. The role of
Ser219Gly, or other common polymorphisms of the PROC, PROCR, and PROS1 genes, in
risk of arterial thrombotic disease or mortality have not been carefully examined.
Here, using a tagSNP approach, and data from the population-based Cardiovascular Health
Study (CHS), we assessed associations between common polymorphisms and haplotypes of
the PROC, PROS1, and PROCR genes and (a) plasma protein C, sEPCR and protein S levels
measured in a cross-sectional sub-sample of 336 participants at study entry, and (b) risk of
incident clinical outcomes (MI, stroke, and mortality) in 4,547 participants during follow-up.
Secondarily, we explored associations of other candidate genes involved in thrombosis,
inflammation, and aging with plasma protein C, sEPCR, and protein S levels.
METHODS
The CHS population, inclusion criteria for the current study, and follow-up for clinical
events, including years of healthy life [12], are described in detail under Supplemental
Methods. A total of 336 men and women with baseline protein C, S and sEPCR
measurements not taking warfarin were included in the baseline cross-sectional analysis.
The number of participants eligible for analysis of clinical events during follow-up was
4,547. All study participants provided written informed consent for use of their DNA for
genetic testing.
Blood collection and analysis
Baseline blood was collected in a fasting state, and a special tube designed to prevent in
vitro clotting activation (SCAT-1, Haematologic Technologies, Inc., Essex Junction, VT)
was used [13]. Blood samples were analyzed at the Central CHS Laboratory at the
University of Vermont. Protein C antigen, free protein S (unbound to C4b-binding protein)
total protein S (free + C4b-binding protein-bound), and sEPCR were measured by enzyme
linked immunosorbent assays (ELISAs) as previously described [14,15]. The assay CVs
were 2.5%, 9.9%, 6.7%, and 3%, respectively.
TagSNP selection
Single nucleotide polymorphisms (SNPs), pair-wise linkage disequilibrium (LD) patterns,
and haplotypes for our candidate genes were identified from the SeattleSNPs candidate gene
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SNP discovery resource and database (http://pga.mbt.washington.edu/). Polymorphic sites
were identified by direct re-sequencing of genomic sequence from 23 European-Americans
encompassing all exons, introns, untranslated regions and ~ 2 kb of additional flanking
sequence on either 5′ or 3′ end. For PROC, PROCR, and PROS1, a total of 39, 13, and 44
polymorphic sites were identified by SeattleSNPs, of which 28, 8, and 17 had minor allele
frequency (MAF)≥10%. TagSNPs were identified using the pair-wise LD binning procedure
implemented in the LDSelect algorithm of Carlson et al [16], at a ≥10% MAF threshold and
a linkage disequilibrium (LD) threshold of r2 ≥ 0.64 to create bins. Using this procedure, we
identified 4 tagSNP bins for PROC, 2 for PROCR, and 4 for PROS1 (see Table 1). One
PROS1 tagSNP bin could not be assayed due to assay failure. Therefore linkage
disequilibrium coverage in PROC, PROS1, and PROCR for untyped SNPs with minor allele
frequencies of 10% or greater was 100%, 75%, and 100%, respectively at an r-squared
threshold of ≥0.64. TagSNPs were similarly selected for the remaining 127 candidate genes
using SeattleSNPs or HapMap databases at an LD threshold of r2 ≥ 0.64 and MAF ≥10%.
SNP genotyping
PROC, PROS1, and PROCR genotyping was performed in all consenting CHS participants
at the Laboratory for Clinical Biochemistry Research (University of Vermont) with the ABI
TaqMan platform using Assays By Design on an ABI 7900 real time thermal cycler under
standard conditions (Applied Biosystems, Foster City, CA). Overall genotype missing rate
was <0.1%, and blind duplicate concordance rates were >99%. Genotype distributions were
in Hardy-Weinberg equilibrium for all PROC, PROCR, and PROS1 tagSNPs, with the
exception of PROS1 rs4857343 (uncorrected p=0.002). Additional genotyping was
performed using the Illumina GoldenGate platform by the Center for Inherited Disease
Research (CIDR; Johns Hopkins University, Baltimore, MD) for 876 tagSNPs covering
common linkage disequilibrium patterns across 127 thrombosis, inflammation, and aging-
related genes, as previously described in detail [17].
Statistical analysis
Our primary hypotheses were to test whether common polymorphisms of the PROC,
PROCR, and PROS1 genes were associated with (a) protein C, sEPCR, and protein S levels;
(b) risk of incident clinical CVD and aging-related outcomes. Secondarily, we also explored
associations of other candidate genes involved in thrombosis, inflammation, and aging on
plasma protein C, sEPCR, and protein S levels. Cross-sectional relationships between
baseline protein C, S and sEPCR measurements were assessed using Spearman’s rank
correlation coefficient (ρ). Associations between individual SNP genotypes and baseline
quantitative phenotypes were assessed using multiple linear regression models. All
regression models were minimally adjusted for age and sex. To reduce the influence of
environmental variation, protein C and protein S regression models were additionally
adjusted for cholesterol and triglycerides (which were strong cross-sectional correlates of
protein C and S levels). Covariate-adjusted mean adjusted plasma anticoagulant levels (and
95% confidence intervals) were estimated for each genotype group from the regression
coefficients (β) and standard errors. Associations between individual tagSNP genotypes and
risk of incident CVD events or mortality during follow-up were assessed using Cox
regression, adjusted for major clinical risk factors (age, sex, diabetes, hypertension, clinical
CVD status, smoking, and serum creatinine). Covariate-adjusted hazard ratios were
estimated from the regression coefficient, assuming a constant effect size for each additional
copy of the minor allele. In analyses of incident MI and stroke during follow-up, we
excluded participants who had experienced an MI (n=447) or stroke (n=165) prior to
baseline. Assessment and adjustment of potential within-Europe population structure during
our primary candidate gene analyses was performed as described under Supplemental
Methods.
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We used various procedures to control for multiple hypotheses testing during our primary
and secondary analyses. For each of our primary candidate genes, we conducted a “gene-
wide” test of significance by performing 100,000 permutations of the data sampled under
the null hypothesis. Empirical p-values were determined by counting the proportion of times
the observed test statistic was greater than the maximum value of the permuted null test
statistics across all SNPs in each gene, thereby accounting for the number of SNPs tested
and the variable correlation structure, while controlling the experiment wise type 1 error rate
at 5% for each gene [18]. We also used statistical methods to infer haplotypes from the
genotype data, using the probability-weighted haplotypes as the unit of analysis [19]. To
further correct our primary analyses of PROC, PROCR, and PROS1 genotypes for testing of
multiple, correlated traits, we conducted an “experiment-wise” test of significance using a
procedure that computes empirical p-values while retaining the original correlation structure
among both genotypes and traits under the null hypothesis by simulation from a multivariate
normal distribution [20]. To correct for multiple comparisons in our secondary analysis of
876 tagSNPs from 130 candidate genes with protein C, S, and sEPCR levels, we assessed
overall statistical significance using the false discovery rate (FDR) q value, which is an
estimate of the proportion of features called significant that are truly null [21].
mRNA expression analysis
To assess associations between PROCR genotype and gene expression, we utilized the
Sanger GENe Expression VARiation project (GENEVAR), a web-accessible collection of
genome-wide microarray-based gene expression measurements obtained from Epstein-Barr
virus-transformed lymphoblastoid cell lines from 60 unrelated European-American HapMap
(CEPH) samples [22]. Differences in mRNA expression levels for genes of interest were
tested between genotype groups using ANOVA.
RESULTS
Participant characteristics among those eligible for each analysis (cross-sectional plasma
phenotype and longitudinal time to clinical event) are summarized in Table 1. The
distributions of protein C, free protein S, and total protein S levels were approximately
normal. As previously reported in other studies [3,4], sEPCR had a multi-modal distribution.
Mean levels of protein C, sEPCR, free protein S, and total protein S were 3.40 ±5.95 mg/L,
222.55 ±90.10 μg/L, 5.01 ±0.94 mg/L, and 22.38 ±3.14 mg/L, respectively. Total protein S
levels were strongly correlated with free protein S (ρ=0.36; p<0.0001) and protein C
(ρ=0.31; p<0.0001). Protein C levels were correlated with free protein S (ρ=0.18; p=0.002)
and sEPCR (ρ=0.21; p=0.0001). Protein C, free protein S and total protein S were strongly
correlated with baseline plasma cholesterol and lipid levels, as previously reported [14].
sEPCR levels initially showed no significant correlation with any traditional cardiovascular
risk factors. However, when adjusted for the strong effect of the Ser219Gly polymorphism,
male sex (p=0.02) and age (p<0.0001) were associated with higher sEPCR levels.
PROC, PROCR, and PROS1 genotype and protein C, S, sEPCR levels
Among the entire CHS sample, the r2 measure of linkage disequilibrium between pairs of
SNPs in each gene were all below 0.65. The associations between PROC, PROCR, PROS1
tagSNPs, haplotypes and their respective plasma phenotypes are shown in Table 2. Under an
additive genetic model, each additional copy of the PROCR Ser219Gly polymorphism was
associated 182 ±6 μg/L higher sEPCR levels, explaining 75% of the phenotypic variation. In
unadjusted models, the minor allele of PROCR rs2069948 appeared to be associated with
lower sEPCR levels (β =−34 ±7 μg/L); however, adjustment for Ser219Gly greatly
weakened the association (β=−3.7 ± 3.8 μg/L; p=0.33). Analysis of the 3 common PROCR
haplotypes confirmed that the haplotype tagged by Ser219Pro (PROCR-3) was strongly
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associated with higher sEPCR levels (p<0.0001) relative to PROCR-1 containing both major
tagSNP alleles, while there was no difference in sEPCR concentration between the
haplotype tagged by rs2069948 (PROCR-2) and PROCR-1 (supplemental Table 1). Each
additional copy of the PROC rs2069901 variant allele was associated with −0.13 ± 0.04
lower mg/L protein C levels (gene-wide p=0.01). PROC haplotypes containing the
rs2069901 variant allele were also associated with lower protein C (supplemental Table 1).
Each additional copy of the PROS1 rs4857343 minor allele (β=−0.28 ± 0.10 mg/L;
p=0.005), or alternatively, the two haplotypes containing the rs4857343 minor allele
(supplemental Table 3), was associated with lower free protein S levels. Upon experiment-
wide correction for testing multiple genes and phenotypes, the association between
Ser219Gly and sEPCR levels was still strongly significant (p<0.0001); however, neither the
protein C nor the free protein S genotype-phenotype associations were significant (p=0.11
and 0.14, respectively).
Additional thrombosis/inflammation gene – protein C, S, EPCR phenotype associations
We screened 876 additional tagSNPs across 130 candidate genes for association with plasma
protein C, S, and sEPCR levels. The tagSNP identifiers, location, regression beta
coefficients, standard errors, p-values and false discovery rate q-values are shown in
Supplemental Table 4. At a false discovery rate threshold of q<0.05, the PROCR Ser219Gly
polymorphism was associated with higher protein C levels (β = 0.63 ± 0.09 mg/L; p-value
9×10−11; q-value <1 ×10−8), explaining 13% of the variation in protein C. The minor allele
of an interleukin-10 gene (IL10) intronic polymorphism on chromosome 1 (rs1878672) was
associated with higher free protein S levels (β = 0.34 ± 0.08 mg/L; p-value 3×10−5; q-value
= 0.03), explaining 5% of the variation in free protein S. The same IL10 rs1878672 variant
was associated with 0.16 ± 0.06 mg/L higher protein C levels (p-value 0.006), though the
protein C association did not meet the same significance threshold (q-value =0.50) as the
free protein S association.
PROC, PROCR, and PROS1 genotype and risk of incident CVD and mortality
There was no evidence for association between PROC or PROS1 genotype and risk of
incident CVD or death. On the other hand, each additional copy of the minor allele of
PROCR rs2069948 was associated with 13% ± 6% (p=0.02) increased risk of stroke and 7%
± 3% increased risk of mortality (p=0.01), even after adjusting for major risk factors (Table
3). Moreover, each additional copy of the PROCR rs2069948 variant was associated 0.32 ±
0.09 fewer years of healthy life (p=0.0003). There was no association between Ser219Gly
and risk of incident CVD or mortality. The PROCR genotype-clinical phenotype results did
not differ among subgroups defined according to age, gender, diabetes, or baseline
subclinical CVD status. Upon experiment-wide correction for multiple testing, only the
PROCR rs2069948 association with years of healthy life remained statistically significant
(p=0.01).
Association between PROCR rs2069948 and cellular gene expression
Examination of linkage disequilibrium patterns surrounding the PROCR gene on
chromosome 20 revealed that PROCR rs2069948 was strongly correlated with several other
SNPs located in PROCR as well as with additional SNPs located outside PROCR.
Supplemental Table 5 shows the location, function, and pair-wise correlation coefficient for
all other SNPs showing strong linkage disequilibrium (r2>0.5) in a 200 kb window
surrounding PROCR rs2069948. We assessed the relationship between PROCR genotype
and lymphoid mRNA expression levels of PROCR and neighboring chromosome 20 genes
in 60 European-American HapMap individuals (Table 4). rs2069948 was associated with
lower PROCR mRNA expression and also with higher and lower mRNA expression levels,
respectively, of EDEM2 (ER degradation-enhancing-mannosidase-like protein 2) and GSS
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(glutathione or GSH synthase). EDEM2 and GSS are both involved in responses to cellular
damage that accumulate during aging. PROCR Ser219Gly polymorphism was neither
associated with PROCR mRNA expression, nor with mRNA expression of any other genes
in the region (Table 4).
DISCUSSION
In older European-American men and women from CHS, the PROCR Ser219Gly variant
was strongly associated with higher sEPCR levels. There were much weaker associations
between common variants of the PROC and PROS1 genes and protein C and free protein S
levels, respectively. In an exploratory analysis that included a larger set of thrombosis- and
inflammation-related genes, an IL10 polymorphism was associated with higher free protein
S and protein C levels. In addition, the PROCR Ser219Gly variant was associated with
higher levels of protein C. There was no evidence of association between Ser219Gly and
risk of clinical CVD. On the other hand, another common PROCR variant rs2069948 was
associated with increased risk of stroke and mortality and decreased healthy survival during
follow-up and with reduced PROCR mRNA expression in lymphoid cells.
Our results confirm that the PROCR Ser219Gly polymorphism is the major determinant of
phenotypic variation in sEPCR [3,4]. In contrast, the majority of inter-individual variation in
protein C and protein S levels does not appear to be explained by common polymorphisms
of PROC or PROS1, respectively. The PROC rs2069901 variant allele weakly associated
with lower protein C levels in CHS tags the same common “CG” haplotype as the PROC
-1654 C/A and -1641 G/T promoter polymorphisms previously reported to be associated
with lower plasma levels [9,10] and lower transcriptional efficiency of protein C [23]. The
PROS1 variant associated with lower free protein S levels in CHS is located in intron 2 and
is in strong linkage disequilibrium with 2 other polymorphisms rs8178583 and rs7650230
located in the 5′ flanking region, but outside of the minimal PROS1 promoter [24,25]. While
our tagSNP approach efficiently captures LD patterns among common SNPs across our
candidate genes, we were not able to capture one common PROS1 LD bin (containing 4
SNPs with MAF ≥10%) due to assay failure. Moreover, the common tagSNP approach
design does not address the possibility that rare variants within these same genes, such as the
previously reported protein S Heerlen Ser460Pro variant [26] (estimated population
prevalence ~ 0.5%), may contribute significantly to phenotypic variance.
Since protein C and sEPCR and levels were moderately correlated, it is interesting to note
that the PROCR Ser219Gly variant was a fairly strong determinant of protein C, explaining
a greater amount of the phenotypic variation than the PROC gene itself. The mechanism of
association between PROCR Ser219Gly and higher sEPCR levels appears to involve
increased EPCR shedding from the endothelium [27], which may result in reduced protein C
activation [28]. Therefore, it is possible that higher sEPCR levels relative to membrane-
bound EPCR associated with Ser219Gly might effectively increase the amount of circulating
protein C by stabilizing it.
We also observed a moderately strong correlation between protein C, protein S, and plasma
lipid levels. Protein C and protein S are functionally- and structurally-related vitamin K-
dependent proteins. It is possible that common polymorphisms of shared regulatory genes
account for at least some of the correlation in their plasma concentration. In this regard, it is
interesting to note that IL10 genotype was associated with both free protein S and protein C
levels. IL10 is located in a region on chromosome 1q32, previously identified as a QTL for
protein S in a genome-wide linkage analysis [7]. The chromosome 1q32 region contains two
genes encoding subunits of C4 binding protein (C4BPA and C4BPB), an inflammation-
sensitive protein. The beta subunit of C4 binding protein binds strongly to protein S and
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effectively determines free protein S levels. C4BPA and C4BPB are located ~300 kb from
the IL10 gene. Examination of HapMap data showed only weak linkage disequilibrium
between the associated IL10 variants and the C4BP gene region, with all pair-wise SNP r2
with IL10 rs4857343 < 0.12. Therefore additional fine-mapping in this extended region on
chromosome 1q32, which also contains several other complement and interleukin-related
genes, will be required to further characterize the variant(s) responsible for the protein S and
protein C phenotypic associations.
A recent report suggested that PROCR Ser219Gly was associated with increased thrombin
generation and increased risk of CHD in men and in diabetics or those with metabolic
syndrome [11]. Our results do not support this finding, either overall or in subgroups defined
according to age, gender, or diabetes. Failure to replicate the Ser219Gly CVD association in
CHS could be related to differences in sample characteristics between studies. Another
potential issue is that the risk associated with PROCR Ser219Gly in the report by Ireland et
al appeared to be limited to homozygotes for the minor Gly219 allele [11]. Gly219
homozygotes comprised only 0.8% of the CHS cohort; therefore even larger sample sizes
may be required to detect a recessive effect.
Based on data from the HapMap, the PROCR rs2069948 variant associated with healthy
aging in CHS is part of an extended haplotype on chromosome 20 that contains 45 other
polymorphisms, including 9 PROCR SNPs in complete linkage disequilibrium, as well as
several variants located in neighboring genes (Supplemental Table 5). One of the SNPs
comprising the risk haplotype, rs6088747, is located within an enhancer region 5.5 kb
upstream of the PROCR translation start site that is essential for PROCR mRNA expression
inendothelium and hematopoietic cells [29]. Another SNP, rs9574, is located within the
proximal 3′ untranslated region of PROCR. It is possible that one or more of these
polymorphism influences PROCR mRNA stability or processing, as suggested by the
observed association between rs2069948 and decreased lymphoid PROCR mRNA
expression. The precise molecular mechanism of this association requires further study,
including assessment of the relative effects of PROCR genotype on membrane versus
soluble forms as well as cell type-specific mRNA expression. It should also be noted that the
same PROCR haplotype tagged by rs2069948 has been associated with higher circulating
activated protein C levels and decreased risk of venous thrombosis [30], though other groups
have reported that the Ser219Gly haplotype, but not the rs2069948 haplotype, is associated
with increased risk of venous thrombosis [3,4].
Because of the anticoagulant, anti-inflammatory, cytoprotective, and immuno-modulatory
properties of the protein C system [1,2], genes encoding protein C pathway components are
potential candidates not only for athero-thrombotic and ischemic conditions [31], but also
for inflammatory and other aging-related disorders. Endothelial protein C receptor is
expressed by various blood cells, and binding of protein C arrests cellular migration [32,33].
The effects of the protein C/EPCR pathway on endothelial or immune cell function may not
only be related to the apparent influence of the PROCR rs2069948 haplotype on healthy
aging, but also to the beneficial effects of activated protein C in the treatment of severe
sepsis [34,35]. Finally, there was some evidence of association between rs2069948 and
expression of other genes in the region, EDEM2 and GSS, which are involved in protein
unfolding response and oxidative damage responses, respectively. These data additionally
suggest the possibility that other cellular processes may play a role in the apparent effect of
the PROCR risk haplotype on thrombosis, mortality or healthy aging.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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